Paul HastingsPresident and CEO at Nkarta Therapeutics
Paul Hastings is Chief Executive Officer and President of Nkarta, a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer. Prior to joining Nkarta, Mr. Hastings was Chairman and CEO of OncoMed. His earlier executive leadership roles include President and CEO of QLT, Inc., President and CEO of Axys Pharmaceuticals, President of Chiron BioPharmaceuticals, a division of Chiron Corporation, President of LXR Biotechnology, President of Genzyme Therapeutics Europe, and President of Genzyme Therapeutics. Paul began his career in sales and marketing with leadership roles at Synergen and Hoffmann-La Roche. Mr. Hastings is currently Lead Independent Director of Pacira Biosciences, Inc. and Director at ViaCyte. He also serves as Chair and member of the Executive Committee of the Biotechnology Innovation Organization (BIO). Previously he served on the Board of Directors of Proteon Therapeutics, Relypsa, Proteolix, and ViaCell. Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.